<p>Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.</p>

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

Sign up to save your podcasts

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

More shows like GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Audio

GRACEcast Radiation Oncology Video

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Kidney Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video